NuCana plc (NCNA) 10-Year Financial Performance & Capital Metrics

NCNA • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutNuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors and in a Phase 1b/2 clinical trial for patients with advanced colorectal cancer; and NUC-7738, a nucleoside analog that is in Phase 1/2 clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.Show more

Revenue $0
EBITDA -$22M +30.8%
Net Income -$19M +31.3%
EPS (Diluted) -3.27 +37.7%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -182.3% -76.1%
ROIC -
Debt/Equity 0.03 +20.0%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Weak momentum: RS Rating 8 (bottom 8%)
✗Shares diluted 12.7% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-5.85%

EPS CAGR

10Y-

5Y-

3Y-

TTM-1794.45%

ROCE

10Y Avg-69.05%

5Y Avg-102.9%

3Y Avg-139.82%

Latest-214.74%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	283K	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-1%	-	-	-	-	-	-
Cost of Goods Sold+	0	0	0	0	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	0	0	283K	0	0	0	0	0	0	0
Gross Margin %	-	-	1%	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-1%	-	-	-	-	-	-
Operating Expenses+	6.91M	9.05M	24.04M	22.03M	25.68M	32.95M	45.36M	43.72M	31.13M	22.9M
OpEx % of Revenue	-	-	84.95%	-	-	-	-	-	-	-
Selling, General & Admin	1.25M	1.14M	4.57M	5.18M	5.95M	7.05M	8.53M	7.29M	6.06M	4.99M
SG&A % of Revenue	-	-	16.16%	-	-	-	-	-	-	-
Research & Development	5.66M	7.9M	17.67M	16.85M	19.73M	25.9M	36.83M	36.43M	25.06M	18.02M
R&D % of Revenue	-	-	62.45%	-	-	-	-	-	-	-
Other Operating Expenses	0	0	1.79M	0	0	0	0	0	0	-101K
Operating Income+	-6.91M	-8.45M	-22.25M	-22.03M	-26.7M	-32.92M	-45.34M	-43.7M	-32.78M	-22.81M
Operating Margin %	-	-	-78.61%	-	-	-	-	-	-	-
Operating Income Growth %	-911.12%	-0.22%	-1.63%	0.01%	-0.21%	-0.23%	-0.38%	0.04%	0.25%	0.3%
EBITDA+	-6.87M	-8.45M	-22.25M	-22.03M	-26.7M	-32.03M	-44.4M	-42.96M	-32.21M	-22.29M
EBITDA Margin %	-	-	-78.61%	-	-	-	-	-	-	-
EBITDA Growth %	-909.22%	-0.23%	-1.63%	0.01%	-0.21%	-0.2%	-0.39%	0.03%	0.25%	0.31%
D&A (Non-Cash Add-back)	44K	101	194	371	718	890K	942K	732K	575K	522K
EBIT	-6.91M	0	0	0	0	0	0	-52.89M	-32.36M	-23M
Net Interest Income+	0	0	0	0	1.05M	246K	103K	669K	-349K	358K
Interest Income	406K	283K	208K	1.06M	1.05M	246K	103K	669K	754K	358K
Interest Expense	0	0	0	0	0	0	0	0	1.1M	0
Other Income/Expense	406K	283K	-3.24M	3.97M	1.05M	-3.25M	-2.46M	5.24M	754K	358K
Pretax Income+	-6.51M	-8.16M	-25.49M	-18.06M	-25.65M	-36.17M	-47.8M	-38.45M	-32.03M	-22.45M
Pretax Margin %	-	-	-90.06%	-	-	-	-	-	-	-
Income Tax+	-1.18M	-2.12M	-2.4M	-4.22M	-4.24M	-5.49M	-7.27M	-6.43M	-4.4M	-3.45M
Effective Tax Rate %	0.82%	0.74%	0.91%	0.77%	0.83%	0.85%	0.85%	0.83%	0.86%	0.85%
Net Income+	-5.33M	-6.05M	-23.09M	-13.84M	-21.41M	-30.68M	-40.53M	-32.02M	-27.63M	-19M
Net Margin %	-	-	-81.57%	-	-	-	-	-	-	-
Net Income Growth %	-862.69%	-0.13%	-2.82%	0.4%	-0.55%	-0.43%	-0.32%	0.21%	0.14%	0.31%
Net Income (Continuing)	-5.33M	-6.05M	-23.09M	-13.84M	-21.41M	-30.68M	-40.53M	-32.02M	-27.63M	-19M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1.75	-2.00	-8.87	-4.25	-6.62	-10.12	-9.75	-6.12	-5.25	-3.27
EPS Growth %	-	-0.14%	-3.44%	0.52%	-0.56%	-0.53%	0.04%	0.37%	0.14%	0.38%
EPS (Basic)	-1.75	-2.00	-8.87	-4.25	-6.75	-10.12	-9.75	-6.25	-5.25	-3.27
Diluted Shares Outstanding	3.09M	3.09M	2.61M	3.2M	3.23M	3.79M	4.16M	5.22M	5.27M	5.94M
Basic Shares Outstanding	3.09M	3.09M	2.61M	3.2M	3.18M	3.79M	4.16M	5.17M	5.27M	5.94M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	30.74M	25.82M	93.98M	83.59M	65.15M	101.81M	71.61M	54.92M	25.02M	12.27M
Cash & Short-Term Investments	29.19M	19.99M	86.7M	76.97M	51.96M	87.36M	60.26M	41.91M	17.23M	6.75M
Cash Only	14.11M	19.99M	86.7M	76.97M	51.96M	87.36M	60.26M	41.91M	17.23M	6.75M
Short-Term Investments	15.07M	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	0	0	0	0	0	50K	5.83M	4.64M
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	-15.02M	3.2M	-3.05M	-1.8M	-13.19K	-14.45K	-11.35K	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	0	0	0	12.96M	0	0
Total Non-Current Assets+	941K	1.4M	2.38M	3.6M	5.12M	5.99M	5.86M	3.33M	2.79M	2.51M
Property, Plant & Equipment	14K	18K	358K	427K	1.11M	1.19M	851K	866K	521K	197K
Fixed Asset Turnover	-	-	0.79x	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	927K	1.38M	1.94M	3.12M	3.96M	4.75M	2.41M	2.37M	2.13M	2.2M
Long-Term Investments	0	0	2.3K	3.55K	5.07K	5.94K	0	3.23K	0	0
Other Non-Current Assets	0	0	-2.3K	-3.55K	-5.07K	-5.94K	2.54M	-3.23K	0	0
Total Assets+	31.68M	27.21M	96.36M	87.19M	70.27M	107.79M	77.47M	58.25M	27.81M	14.77M
Asset Turnover	-	-	0.00x	-	-	-	-	-	-	-
Asset Growth %	887.16%	-0.14%	2.54%	-0.1%	-0.19%	0.53%	-0.28%	-0.25%	-0.52%	-0.47%
Total Current Liabilities+	1.73M	1.97M	2.92M	5.57M	6.18M	8.15M	11.72M	19.31M	12.68M	8.67M
Accounts Payable	507K	728K	1.12M	2.46M	2.41M	2.26M	1.83M	4.8M	3.38M	2.71M
Days Payables Outstanding	-	-	-	-	-	-	-	-	-	-
Short-Term Debt	0	0	0	0	268K	278K	207K	243K	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	1.16M	1.18M	1.64M	0	3.07M	5.16M	9.3M	3.86M	0	40K
Current Ratio	17.82x	13.09x	32.22x	15.02x	10.54x	12.49x	6.11x	2.84x	1.97x	1.42x
Quick Ratio	26.53x	11.46x	33.26x	15.34x	10.54x	12.49x	6.11x	2.84x	1.97x	1.42x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	18K	26K	564K	413K	210K	442K	248K	154K
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	538K	367K	164K	396K	190K	117K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	18K	26K	26K	46K	46K	46K	58K	37K
Total Liabilities	1.73M	1.97M	2.94M	5.59M	6.75M	8.56M	11.93M	19.75M	12.92M	8.82M
Total Debt+	0	0	0	0	806K	645K	371K	639K	396K	190K
Net Debt	-14.11M	-19.99M	-86.7M	-76.97M	-51.16M	-86.71M	-59.89M	-41.27M	-16.83M	-6.56M
Debt / Equity	-	-	-	-	0.01x	0.01x	0.01x	0.02x	0.03x	0.03x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-	-29.72x	-
Total Equity+	29.96M	25.24M	93.42M	81.59M	63.52M	99.23M	65.55M	38.5M	14.89M	5.95M
Equity Growth %	867.2%	-0.16%	2.7%	-0.13%	-0.22%	0.56%	-0.34%	-0.41%	-0.61%	-0.6%
Book Value per Share	9.70	8.18	35.83	25.52	19.65	26.20	15.74	7.37	2.83	1.00
Total Shareholders' Equity	29.96M	25.24M	93.42M	81.59M	63.52M	99.23M	65.55M	38.5M	14.89M	5.95M
Common Stock	659K	663K	80.51M	80.72M	80.84M	2.05M	2.09M	2.1M	2.11M	5.68M
Retained Earnings	-16.22M	-22.26M	-45.16M	-58.81M	-80.06M	-110.59M	-149.73M	-180.57M	-207.71M	-224.29M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	2.95M	4.06M	58.07M	59.69M	62.74M	66.89M	72.14M	75.87M	79.17M	78.42M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-4.47M	-9.26M	-8.71M	-12.22M	-23.83M	-21.62M	-23.82M	-23.16M	-26.44M	-19.12M
Operating CF Margin %	-	-	-30.77%	-	-	-	-	-	-	-
Operating CF Growth %	0.15%	-1.07%	0.06%	-0.4%	-0.95%	0.09%	-0.1%	0.03%	-0.14%	0.28%
Net Income	-5.33M	-6.05M	-23.09M	-13.84M	-21.41M	-30.68M	-40.53M	-32.02M	-27.63M	-19M
Depreciation & Amortization	44K	101K	194K	371K	718K	890K	942K	732K	575K	522K
Stock-Based Compensation	785K	1.13M	11.73M	1.79M	3.23M	4.3M	6.66M	4.89M	3.86M	1.65M
Deferred Taxes	-1.18M	-2.12M	-2.4M	-4.22M	-4.24M	-5.49M	-7.27M	-6.43M	-4.4M	-3.45M
Other Non-Cash Items	625K	819K	3.45M	200K	-24K	7.41M	12.28M	5.95M	2.44M	3.35M
Working Capital Changes	587K	-3.15M	1.4M	3.47M	-2.1M	1.95M	4.09M	3.72M	-1.28M	-2.18M
Change in Receivables	36K	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	133K	220K	392K	1.33M	-43K	-155K	-428K	2.97M	-1.43M	-670K
Cash from Investing+	-181K	14.93M	-933K	-651K	-145K	-1.31M	-3.56M	120K	2.89M	79K
Capital Expenditures	-6K	-554K	-370K	-210K	-46K	-361K	-64K	-518K	-4K	-4K
CapEx % of Revenue	-	-	1.31%	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-100K	410K	-563K	-441K	-99K	-952K	-3.5M	638K	2.89M	83K
Cash from Financing+	0	200K	77.75M	207K	-47K	61.8M	-98K	-161K	-53K	8.18M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	200K	-2.09M	207K	-47K	-4.78M	198K	-161K	-32K	-322K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-4.86M	-9.82M	-9.8M	-13.85M	-25.09M	-23.25M	-24.89M	-23.68M	-26.92M	-19.41M
FCF Margin %	-	-	-34.64%	-	-	-	-	-	-	-
FCF Growth %	0.08%	-1.02%	0%	-0.41%	-0.81%	0.07%	-0.07%	0.05%	-0.14%	0.28%
FCF per Share	-1.58	-3.18	-3.76	-4.33	-7.76	-6.14	-5.98	-4.53	-5.11	-3.27
FCF Conversion (FCF/Net Income)	0.84x	1.53x	0.38x	0.88x	1.11x	0.70x	0.59x	0.72x	0.96x	1.01x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-35.55%	-21.92%	-38.91%	-15.82%	-29.51%	-37.7%	-49.2%	-61.55%	-103.51%	-182.3%
Return on Invested Capital (ROIC)	-65.44%	-60.06%	-278.82%	-291.43%	-235.75%	-198.45%	-374.26%	-2272.68%	-	-
Gross Margin	-	-	100%	-	-	-	-	-	-	-
Net Margin	-	-	-8157.24%	-	-	-	-	-	-	-
Debt / Equity	-	-	-	-	0.01x	0.01x	0.01x	0.02x	0.03x	0.03x
Interest Coverage	-	-	-	-	-	-	-	-	-29.72x	-
FCF Conversion	0.84x	1.53x	0.38x	0.88x	1.11x	0.70x	0.59x	0.72x	0.96x	1.01x
Revenue Growth	-	-	-	-100%	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

NuCana plc (NCNA) grew revenue by 0.0% over the past year. Growth has been modest.

NuCana plc (NCNA) reported a net loss of $27.5M for fiscal year 2024.

Dividend & Returns

NuCana plc (NCNA) has a return on equity (ROE) of -182.3%. Negative ROE indicates the company is unprofitable.

NuCana plc (NCNA) had negative free cash flow of $14.0M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

NuCana plc (NCNA) 10-Year Financial Performance & Capital Metrics

NCNA • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

Revenue $0
EBITDA -$22M +30.8%
Net Income -$19M +31.3%
EPS (Diluted) -3.27 +37.7%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -182.3% -76.1%
ROIC -
Debt/Equity 0.03 +20.0%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Weak momentum: RS Rating 8 (bottom 8%)
✗Shares diluted 12.7% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-5.85%

EPS CAGR

10Y-

5Y-

3Y-

TTM-1794.45%

ROCE

10Y Avg-69.05%

5Y Avg-102.9%

3Y Avg-139.82%

Latest-214.74%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	283K	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-1%	-	-	-	-	-	-
Cost of Goods Sold+	0	0	0	0	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	0	0	283K	0	0	0	0	0	0	0
Gross Margin %	-	-	1%	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-1%	-	-	-	-	-	-
Operating Expenses+	6.91M	9.05M	24.04M	22.03M	25.68M	32.95M	45.36M	43.72M	31.13M	22.9M
OpEx % of Revenue	-	-	84.95%	-	-	-	-	-	-	-
Selling, General & Admin	1.25M	1.14M	4.57M	5.18M	5.95M	7.05M	8.53M	7.29M	6.06M	4.99M
SG&A % of Revenue	-	-	16.16%	-	-	-	-	-	-	-
Research & Development	5.66M	7.9M	17.67M	16.85M	19.73M	25.9M	36.83M	36.43M	25.06M	18.02M
R&D % of Revenue	-	-	62.45%	-	-	-	-	-	-	-
Other Operating Expenses	0	0	1.79M	0	0	0	0	0	0	-101K
Operating Income+	-6.91M	-8.45M	-22.25M	-22.03M	-26.7M	-32.92M	-45.34M	-43.7M	-32.78M	-22.81M
Operating Margin %	-	-	-78.61%	-	-	-	-	-	-	-
Operating Income Growth %	-911.12%	-0.22%	-1.63%	0.01%	-0.21%	-0.23%	-0.38%	0.04%	0.25%	0.3%
EBITDA+	-6.87M	-8.45M	-22.25M	-22.03M	-26.7M	-32.03M	-44.4M	-42.96M	-32.21M	-22.29M
EBITDA Margin %	-	-	-78.61%	-	-	-	-	-	-	-
EBITDA Growth %	-909.22%	-0.23%	-1.63%	0.01%	-0.21%	-0.2%	-0.39%	0.03%	0.25%	0.31%
D&A (Non-Cash Add-back)	44K	101	194	371	718	890K	942K	732K	575K	522K
EBIT	-6.91M	0	0	0	0	0	0	-52.89M	-32.36M	-23M
Net Interest Income+	0	0	0	0	1.05M	246K	103K	669K	-349K	358K
Interest Income	406K	283K	208K	1.06M	1.05M	246K	103K	669K	754K	358K
Interest Expense	0	0	0	0	0	0	0	0	1.1M	0
Other Income/Expense	406K	283K	-3.24M	3.97M	1.05M	-3.25M	-2.46M	5.24M	754K	358K
Pretax Income+	-6.51M	-8.16M	-25.49M	-18.06M	-25.65M	-36.17M	-47.8M	-38.45M	-32.03M	-22.45M
Pretax Margin %	-	-	-90.06%	-	-	-	-	-	-	-
Income Tax+	-1.18M	-2.12M	-2.4M	-4.22M	-4.24M	-5.49M	-7.27M	-6.43M	-4.4M	-3.45M
Effective Tax Rate %	0.82%	0.74%	0.91%	0.77%	0.83%	0.85%	0.85%	0.83%	0.86%	0.85%
Net Income+	-5.33M	-6.05M	-23.09M	-13.84M	-21.41M	-30.68M	-40.53M	-32.02M	-27.63M	-19M
Net Margin %	-	-	-81.57%	-	-	-	-	-	-	-
Net Income Growth %	-862.69%	-0.13%	-2.82%	0.4%	-0.55%	-0.43%	-0.32%	0.21%	0.14%	0.31%
Net Income (Continuing)	-5.33M	-6.05M	-23.09M	-13.84M	-21.41M	-30.68M	-40.53M	-32.02M	-27.63M	-19M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1.75	-2.00	-8.87	-4.25	-6.62	-10.12	-9.75	-6.12	-5.25	-3.27
EPS Growth %	-	-0.14%	-3.44%	0.52%	-0.56%	-0.53%	0.04%	0.37%	0.14%	0.38%
EPS (Basic)	-1.75	-2.00	-8.87	-4.25	-6.75	-10.12	-9.75	-6.25	-5.25	-3.27
Diluted Shares Outstanding	3.09M	3.09M	2.61M	3.2M	3.23M	3.79M	4.16M	5.22M	5.27M	5.94M
Basic Shares Outstanding	3.09M	3.09M	2.61M	3.2M	3.18M	3.79M	4.16M	5.17M	5.27M	5.94M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	30.74M	25.82M	93.98M	83.59M	65.15M	101.81M	71.61M	54.92M	25.02M	12.27M
Cash & Short-Term Investments	29.19M	19.99M	86.7M	76.97M	51.96M	87.36M	60.26M	41.91M	17.23M	6.75M
Cash Only	14.11M	19.99M	86.7M	76.97M	51.96M	87.36M	60.26M	41.91M	17.23M	6.75M
Short-Term Investments	15.07M	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	0	0	0	0	0	50K	5.83M	4.64M
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	-15.02M	3.2M	-3.05M	-1.8M	-13.19K	-14.45K	-11.35K	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	0	0	0	12.96M	0	0
Total Non-Current Assets+	941K	1.4M	2.38M	3.6M	5.12M	5.99M	5.86M	3.33M	2.79M	2.51M
Property, Plant & Equipment	14K	18K	358K	427K	1.11M	1.19M	851K	866K	521K	197K
Fixed Asset Turnover	-	-	0.79x	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	927K	1.38M	1.94M	3.12M	3.96M	4.75M	2.41M	2.37M	2.13M	2.2M
Long-Term Investments	0	0	2.3K	3.55K	5.07K	5.94K	0	3.23K	0	0
Other Non-Current Assets	0	0	-2.3K	-3.55K	-5.07K	-5.94K	2.54M	-3.23K	0	0
Total Assets+	31.68M	27.21M	96.36M	87.19M	70.27M	107.79M	77.47M	58.25M	27.81M	14.77M
Asset Turnover	-	-	0.00x	-	-	-	-	-	-	-
Asset Growth %	887.16%	-0.14%	2.54%	-0.1%	-0.19%	0.53%	-0.28%	-0.25%	-0.52%	-0.47%
Total Current Liabilities+	1.73M	1.97M	2.92M	5.57M	6.18M	8.15M	11.72M	19.31M	12.68M	8.67M
Accounts Payable	507K	728K	1.12M	2.46M	2.41M	2.26M	1.83M	4.8M	3.38M	2.71M
Days Payables Outstanding	-	-	-	-	-	-	-	-	-	-
Short-Term Debt	0	0	0	0	268K	278K	207K	243K	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	1.16M	1.18M	1.64M	0	3.07M	5.16M	9.3M	3.86M	0	40K
Current Ratio	17.82x	13.09x	32.22x	15.02x	10.54x	12.49x	6.11x	2.84x	1.97x	1.42x
Quick Ratio	26.53x	11.46x	33.26x	15.34x	10.54x	12.49x	6.11x	2.84x	1.97x	1.42x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	18K	26K	564K	413K	210K	442K	248K	154K
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	538K	367K	164K	396K	190K	117K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	18K	26K	26K	46K	46K	46K	58K	37K
Total Liabilities	1.73M	1.97M	2.94M	5.59M	6.75M	8.56M	11.93M	19.75M	12.92M	8.82M
Total Debt+	0	0	0	0	806K	645K	371K	639K	396K	190K
Net Debt	-14.11M	-19.99M	-86.7M	-76.97M	-51.16M	-86.71M	-59.89M	-41.27M	-16.83M	-6.56M
Debt / Equity	-	-	-	-	0.01x	0.01x	0.01x	0.02x	0.03x	0.03x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-	-29.72x	-
Total Equity+	29.96M	25.24M	93.42M	81.59M	63.52M	99.23M	65.55M	38.5M	14.89M	5.95M
Equity Growth %	867.2%	-0.16%	2.7%	-0.13%	-0.22%	0.56%	-0.34%	-0.41%	-0.61%	-0.6%
Book Value per Share	9.70	8.18	35.83	25.52	19.65	26.20	15.74	7.37	2.83	1.00
Total Shareholders' Equity	29.96M	25.24M	93.42M	81.59M	63.52M	99.23M	65.55M	38.5M	14.89M	5.95M
Common Stock	659K	663K	80.51M	80.72M	80.84M	2.05M	2.09M	2.1M	2.11M	5.68M
Retained Earnings	-16.22M	-22.26M	-45.16M	-58.81M	-80.06M	-110.59M	-149.73M	-180.57M	-207.71M	-224.29M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	2.95M	4.06M	58.07M	59.69M	62.74M	66.89M	72.14M	75.87M	79.17M	78.42M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-4.47M	-9.26M	-8.71M	-12.22M	-23.83M	-21.62M	-23.82M	-23.16M	-26.44M	-19.12M
Operating CF Margin %	-	-	-30.77%	-	-	-	-	-	-	-
Operating CF Growth %	0.15%	-1.07%	0.06%	-0.4%	-0.95%	0.09%	-0.1%	0.03%	-0.14%	0.28%
Net Income	-5.33M	-6.05M	-23.09M	-13.84M	-21.41M	-30.68M	-40.53M	-32.02M	-27.63M	-19M
Depreciation & Amortization	44K	101K	194K	371K	718K	890K	942K	732K	575K	522K
Stock-Based Compensation	785K	1.13M	11.73M	1.79M	3.23M	4.3M	6.66M	4.89M	3.86M	1.65M
Deferred Taxes	-1.18M	-2.12M	-2.4M	-4.22M	-4.24M	-5.49M	-7.27M	-6.43M	-4.4M	-3.45M
Other Non-Cash Items	625K	819K	3.45M	200K	-24K	7.41M	12.28M	5.95M	2.44M	3.35M
Working Capital Changes	587K	-3.15M	1.4M	3.47M	-2.1M	1.95M	4.09M	3.72M	-1.28M	-2.18M
Change in Receivables	36K	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	133K	220K	392K	1.33M	-43K	-155K	-428K	2.97M	-1.43M	-670K
Cash from Investing+	-181K	14.93M	-933K	-651K	-145K	-1.31M	-3.56M	120K	2.89M	79K
Capital Expenditures	-6K	-554K	-370K	-210K	-46K	-361K	-64K	-518K	-4K	-4K
CapEx % of Revenue	-	-	1.31%	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-100K	410K	-563K	-441K	-99K	-952K	-3.5M	638K	2.89M	83K
Cash from Financing+	0	200K	77.75M	207K	-47K	61.8M	-98K	-161K	-53K	8.18M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	200K	-2.09M	207K	-47K	-4.78M	198K	-161K	-32K	-322K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-4.86M	-9.82M	-9.8M	-13.85M	-25.09M	-23.25M	-24.89M	-23.68M	-26.92M	-19.41M
FCF Margin %	-	-	-34.64%	-	-	-	-	-	-	-
FCF Growth %	0.08%	-1.02%	0%	-0.41%	-0.81%	0.07%	-0.07%	0.05%	-0.14%	0.28%
FCF per Share	-1.58	-3.18	-3.76	-4.33	-7.76	-6.14	-5.98	-4.53	-5.11	-3.27
FCF Conversion (FCF/Net Income)	0.84x	1.53x	0.38x	0.88x	1.11x	0.70x	0.59x	0.72x	0.96x	1.01x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-35.55%	-21.92%	-38.91%	-15.82%	-29.51%	-37.7%	-49.2%	-61.55%	-103.51%	-182.3%
Return on Invested Capital (ROIC)	-65.44%	-60.06%	-278.82%	-291.43%	-235.75%	-198.45%	-374.26%	-2272.68%	-	-
Gross Margin	-	-	100%	-	-	-	-	-	-	-
Net Margin	-	-	-8157.24%	-	-	-	-	-	-	-
Debt / Equity	-	-	-	-	0.01x	0.01x	0.01x	0.02x	0.03x	0.03x
Interest Coverage	-	-	-	-	-	-	-	-	-29.72x	-
FCF Conversion	0.84x	1.53x	0.38x	0.88x	1.11x	0.70x	0.59x	0.72x	0.96x	1.01x
Revenue Growth	-	-	-	-100%	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

NuCana plc (NCNA) grew revenue by 0.0% over the past year. Growth has been modest.

NuCana plc (NCNA) reported a net loss of $27.5M for fiscal year 2024.

Dividend & Returns

NuCana plc (NCNA) has a return on equity (ROE) of -182.3%. Negative ROE indicates the company is unprofitable.

NuCana plc (NCNA) had negative free cash flow of $14.0M in fiscal year 2024, likely due to heavy capital investments.